Is AQSZF or EQR a better dividend investment in 2026?

AQSZF currently yields 51282.05% with a 5% 5-year dividend growth rate. EQR yields 5.87% with 5% growth. The better choice depends on your goal: AQSZF offers higher current income.

What is the dividend yield difference between AQSZF and EQR?

AQSZF has a forward dividend yield of 51282.05% ($2.00/share annually). EQR yields 5.87% ($3.47/share annually). The yield gap is 51276.18 percentage points.

Home › Compare › AQSZF vs EQR

AQSZF vs EQR: Dividend Comparison 2026

AQSZF yields 51282.05% · EQR yields 5.87%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 AQSZF wins by $6.164318307325471e+23M in total portfolio value

INVESTMENT

TIME HORIZON10 years

AQSZF

● Live price

51282.05%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$6.164318307325471e+23M

Annual income

$614,076,267,853,163,140,000,000,000,000.00

Full AQSZF calculator →

EQR

● Live price

5.87%

Share price

$59.15

Annual div

$3.47

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$47.8K

Annual income

$5,475.61

Full EQR calculator →

Portfolio growth — AQSZF vs EQR

📍 AQSZF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	AQSZF	EQR
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, AQSZF + EQR cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

AQSZF pays

EQR pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AQSZF

Annual income on $10K today (after 15% tax)

$4,358,974.36/yr

After 10yr DRIP, annual income (after tax)

$521,964,827,675,188,650,000,000,000,000.00/yr

EQR

Annual income on $10K today (after 15% tax)

$499.01/yr

After 10yr DRIP, annual income (after tax)

$4,654.27/yr

At 15% tax rate, AQSZF beats the other by $521,964,827,675,188,650,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AQSZF + EQR for your $10,000?

AQSZF: 50%EQR: 50%

100% EQR50/50100% AQSZF

Portfolio after 10yr

$3.0821591536627355e+23M

Annual income

$307,038,133,926,581,570,000,000,000,000.00/yr

Blended yield

99.62%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

AQSZF

No analyst data

Altman Z

-297.9

Piotroski

3/9

EQR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$70.35

+18.9% upside vs current

Range: $63.00 — $78.50

Altman Z

1.8

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AQSZF buys

EQR buys

No recent congressional trades found for AQSZF or EQR in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricAQSZFEQR

Forward yield	51282.05% ✓	5.87%
Annual dividend / share	$2.00	$3.47 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$6.164318307325471e+23M	$47.8K ✓
Annual income after 10y	$614,076,267,853,163,140,000,000,000,000.00 ✓	$5,475.61
Total dividends collected	$6.16277212408334e+23M	$23.0K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	REIT

Year-by-year: AQSZF vs EQR ($10,000, DRIP)

Year	AQSZF Portfolio	AQSZF Income/yr	EQR Portfolio	EQR Income/yr	Gap
1← crossover	$5,138,905	$5,128,205.13	$11,380	$679.82	+$5.13M → AQSZF
2	$2,468,429,435	$2,462,930,806.71	$13,014	$837.25	+$2468.42M → AQSZF
3	$1,108,293,458,836	$1,105,652,239,339.88	$14,961	$1,036.20	+$1108293.44M → AQSZF
4	$465,133,359,857,093	$463,947,485,856,138.75	$17,297	$1,289.22	+$465133359.84M → AQSZF
5	$182,471,032,796,869,920	$181,973,340,101,822,850.00	$20,121	$1,613.15	+$182471032796.85M → AQSZF
6	$66,912,846,333,441,070,000	$66,717,602,328,348,430,000.00	$23,561	$2,030.84	+$66912846333441.05M → AQSZF
7	$22,936,650,503,380,730,000,000	$22,865,053,757,803,946,000,000.00	$27,783	$2,573.54	+$22936650503380732.00M → AQSZF
8	$7,349,564,359,975,759,000,000,000	$7,325,022,143,937,141,000,000,000.00	$33,013	$3,284.39	+$7349564359975758848.00M → AQSZF
9	$2,201,460,634,938,307,300,000,000,000	$2,193,596,601,073,133,400,000,000,000.00	$39,547	$4,223.51	+$2.2014606349383072e+21M → AQSZF
10	$616,431,830,732,547,100,000,000,000,000	$614,076,267,853,163,140,000,000,000,000.00	$47,791	$5,475.61	+$6.164318307325471e+23M → AQSZF

AQSZF vs EQR: Complete Analysis 2026

AQSZF — Stock

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Full AQSZF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

📬

Get this AQSZF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AQSZF vs SCHD AQSZF vs JEPI AQSZF vs O AQSZF vs KO AQSZF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.